W
Wendy P. J. den Elzen
Researcher at Leiden University Medical Center
Publications - 100
Citations - 5074
Wendy P. J. den Elzen is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Population & Subclinical infection. The author has an hindex of 30, co-authored 89 publications receiving 4220 citations. Previous affiliations of Wendy P. J. den Elzen include American Medical Association & Newcastle University.
Papers
More filters
Journal ArticleDOI
Subclinical hypothyroidism and the risk of coronary heart disease and mortality.
Nicolas Rodondi,Wendy P. J. den Elzen,Douglas C. Bauer,Anne R. Cappola,Salman Razvi,John P. Walsh,Bjørn Olav Åsvold,Giorgio Iervasi,Misa Imaizumi,Tinh-Hai Collet,Alexandra Bremner,Patrick Maisonneuve,José Augusto Sgarbi,Kay-Tee Khaw,Mark Vanderpump,Anne B. Newman,Jacques Cornuz,Jayne A. Franklyn,Rudi G. J. Westendorp,Eric Vittinghoff,Jacobijn Gussekloo +20 more
TL;DR: Subclinical hypothyroidism is associated with an increased risk of CHD events and CHD mortality in those with higher TSH levels, particularly inThose with a TSH concentration of 10 mIU/L or greater.
Journal ArticleDOI
Subclinical Hyperthyroidism and the Risk of Coronary Heart Disease and Mortality
Tinh-Hai Collet,Jacobijn Gussekloo,Douglas C. Bauer,Wendy P. J. den Elzen,Anne R. Cappola,Philippe Balmer,Giorgio Iervasi,Bjørn Olav Åsvold,José Augusto Sgarbi,Henry Völzke,Baris Gencer,Rui M. B. Maciel,Sabrina Molinaro,Alexandra Bremner,Robert Luben,Patrick Maisonneuve,Jacques Cornuz,Anne B. Newman,Kay-Tee Khaw,Rudi G. J. Westendorp,Jayne A. Franklyn,Eric Vittinghoff,John P. Walsh,Nicolas Rodondi +23 more
TL;DR: Endogenous subclinical hyperthyroidism is associated with increased risks of total,CHD mortality, and incident AF, with highest risks of CHD mortality and AF when thyrotropin level is lower than 0.10 mIU/L.
Journal ArticleDOI
Subclinical Thyroid Dysfunction and the Risk of Heart Failure Events An Individual Participant Data Analysis From 6 Prospective Cohorts
Baris Gencer,Tinh-Hai Collet,Vanessa Virgini,Douglas C. Bauer,Jacobijn Gussekloo,Anne R. Cappola,David Nanchen,Wendy P. J. den Elzen,Philippe Balmer,Robert Luben,Massimo Iacoviello,Vincenzo Triggiani,Jacques Cornuz,Anne B. Newman,Kay-Tee Khaw,J. Wouter Jukema,Rudi G. J. Westendorp,Eric Vittinghoff,Drahomir Aujesky,Nicolas Rodondi +19 more
TL;DR: In this paper, a pooled analysis of individual participant data using all available prospective cohorts with thyroid function tests and subsequent follow-up of heart failure events was performed, and the last two with normal free thyroxine levels.
Journal ArticleDOI
Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study.
Wouter de Ruijter,Rudi G. J. Westendorp,Willem J J Assendelft,Wendy P. J. den Elzen,Anton J. M. de Craen,Saskia le Cessie,Jacobijn Gussekloo +6 more
TL;DR: In very old people from the general population with no history of cardiovascular disease, concentrations of homocysteine alone can accurately identify those at high risk of cardiovascular mortality, whereas classic risk factors included in the Framingham risk score do not.
Journal ArticleDOI
Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.
David J. Stott,Nicolas Rodondi,Patricia M. Kearney,Ian Ford,Rudi G. J. Westendorp,Simon P. Mooijaart,Naveed Sattar,Carole E. Aubert,Drahomir Aujesky,Douglas C. Bauer,Christine Baumgartner,Manuel R. Blum,John Browne,Stephen Byrne,Tinh-Hai Collet,Olaf M. Dekkers,Wendy P. J. den Elzen,Robert S. Du Puy,Graham Ellis,Martin Feller,Carmen Floriani,Kirsty Hendry,Caroline Hurley,J. Wouter Jukema,Sharon Kean,Maria Kelly,Danielle Krebs,Peter Langhorne,Gemma McCarthy,Vera J. C. McCarthy,Alex McConnachie,Mairi McDade,Martina Messow,Anne Marie O'Flynn,David O'Riordan,Rosalinde K. E. Poortvliet,Terence J. Quinn,Audrey Russell,Carol Sinnott,Jan W. A. Smit,H. Anette Van Dorland,Kieran A. Walsh,Elaine Walsh,Torquil Watt,Robbie Wilson,Jacobijn Gussekloo +45 more
TL;DR: Levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism and there was no significant excess of serious adverse events prespecified as being of special interest.